Aviado · Research
Longevity Daily
Thursday, August 13, 2026
Listen
Today's Brief
Brain aging takes center stage today: Nature reports on a controversial Alzheimer's lymphatic surgery claimed to reverse symptoms, and new Cornell Medicine research shows how senescent immune cells actively drive cognitive decline. Nature Medicine delivers a pointed critique of the supplement space, revealing new data showing blood NAD+ levels don't actually decline with age — challenging the premise behind one of the field's most popular interventions. A landmark Lancet RCT finds that cognitive behavioral therapy for insomnia measurably slows biological aging pace, while a UC Berkeley team's cheap three-drug senolytic cocktail extends lifespan in old mice.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
A Controversial Alzheimer's Surgery Claims to Reverse Symptoms — Here's What Scientists Know
A surgical procedure targeting the brain's lymphatic drainage system is generating both extraordinary excitement and pointed scientific skepticism after surgeons reported apparent reversal of Alzheimer's symptoms in select patients. The operation aims to improve clearance of amyloid and tau waste products by widening or reopening lymphatic channels that drain the brain — an approach rooted in over a decade of research into the glymphatic system. Scientists urge caution: there are no large-scale randomized trial data yet, and enthusiasm is running well ahead of evidence. Still, this represents one of the boldest mechanistic bets in Alzheimer's research in years, and one worth tracking closely as case series accumulate.
Read more →Senescent Brain Immune Cells Secrete a Protein That Damages Surrounding Neurons
Weill Cornell Medicine researchers have identified that senescent microglia — brain-resident immune cells that have reached a burned-out, "old-age" state — secrete a specific protein that causes measurable dysfunction in neighboring neurons and other brain cells. The findings add important mechanistic detail to why clearing senescent cells from the brain may protect cognitive function with age, and point to the secreted protein itself as a potential drug target. This is early-stage research, but it strengthens the scientific case for brain-targeted senolytic strategies.
Read more →Poor Sleep Enlarges a Key Brain Structure Tied to Neurodegeneration
A study from the IGNITE Study published in Alzheimer's & Dementia finds that older adults with poor sleep quality have significantly greater choroid plexus volume — and that enlargement of this structure is linked to neuroinflammation, neurodegeneration, and cognitive deficits. The choroid plexus regulates cerebrospinal fluid production and brain waste clearance, meaning disrupted sleep may compound the brain's already-taxed cleaning system in a compounding feedback loop. If sleep quality isn't already a priority in your health stack, this is another reason to move it to the top.
Read more →Supplements & Compounds
Nature Medicine: Anti-Aging Supplements Need Less Hype and Far More Clinical Evidence
A sharply worded commentary in Nature Medicine argues that clinical evidence for anti-aging treatments in humans remains sparse — and specifically calls out NAD+ supplementation, noting that a recent study found blood NAD+ levels remain stable and do not decline with aging, undermining the core rationale for supplementing it. The authors push for reliable biomarkers of aging and rigorous human trial data before widespread clinical or consumer adoption. If you're spending on NAD+ precursors, this is the most important thing you'll read this week.
Read more →Research & Papers
A Cheap Three-Drug Cocktail Exploits Senescent Cells' Metabolic Weakness — and Old Mice Live Longer
UC Berkeley researchers combined two inexpensive, widely available metabolic drugs — dichloroacetate and metformin — with a ten-fold-reduced dose of the experimental senolytic navitoclax to create a three-drug cocktail called DMA. The core insight is that both cancer cells and senescent cells share a metabolic vulnerability: leaky, inefficient mitochondria and over-reliance on glycolysis. By targeting this weakness, DMA clears senescent cells while dramatically reducing the toxic dose of navitoclax needed — and old mice treated with the cocktail showed extended lifespan. The use of two repurposed, low-cost drugs makes this potentially translatable, though human trials remain the essential next step.
Read more →How Fast You're Biologically Aging Predicts Your Dementia Risk and Brain Volume Loss
A study published in Alzheimer's & Dementia finds that accelerated biological aging — quantified via established biomarkers — is independently associated with lower brain volumes and significantly higher risk for incident dementia. The finding suggests that your general rate of biological aging, not just genetics or disease-specific factors, is a meaningful and potentially modifiable driver of cognitive decline. Epigenetic clocks and pace-of-aging metrics like DunedinPACE are increasingly relevant tools for assessing your personal neurodegeneration risk.
Read more →Aviado Research: Evidence-Based Analysis on the Longevity Intervention Landscape
Aviado Research's latest analysis cuts through the noise to assess what the current science actually supports across the longevity intervention landscape. At a moment when Nature Medicine is calling out the field's evidence gaps — and when promising mouse data on senolytics and cheap drug cocktails is raising expectations — rigorous, synthesis-driven analysis is more valuable than ever. Read the full analysis for Aviado's evidence-based take on what's worth your attention.
Read the full Aviado analysis →Lifestyle & Nutrition
Treating Insomnia With CBT Slowed Biological Aging in a Randomized Controlled Trial
A secondary analysis of a randomized controlled trial in 92 adults aged 60+ — published in The Lancet Healthy Longevity — found that cognitive behavioral therapy for insomnia (CBT-I) significantly slowed the pace of biological aging as measured by DunedinPACE, a leading epigenetic clock, compared to sleep education therapy alone (-0.02, FDR-adjusted p=0.03). CBT-I recipients were also more than twice as likely to achieve full insomnia remission (34% vs. 13%). This is one of the strongest human trial signals yet that treating insomnia isn't just about sleeping better — it may actually slow how fast you age at a cellular level. The sample is modest (n=92) and the epigenetic effect size is small, but the direction of evidence is striking.
Read more →Metformin May Be Canceling Out the Cardiometabolic Benefits of Your Workout
A double-blind, placebo-controlled trial (n=91) found that taking metformin at 2,000 mg/day significantly blunted the cardiometabolic improvements normally gained from both low-intensity and high-intensity exercise over 16 weeks. For the growing cohort of people taking metformin as a longevity drug — not just for diabetes management — this is a serious caveat: the drug may be undermining the very adaptations exercise is supposed to deliver. If you're stacking metformin with a dedicated training protocol, the evidence suggests you may need to weigh that tradeoff carefully.
Read more →Industry & Policy
$101 Million XPRIZE Healthspan Advances 20 Finalist Teams, Names UCSD as Clinical Testing Hub
The $101 million XPRIZE Healthspan competition has moved 20 teams into its finals round, designating UC San Diego as the central laboratory for coordinated clinical trials slated to run from 2026 through 2029. The competition is one of the largest structured incentive prizes ever placed on demonstrating meaningful healthspan extension in humans — and this milestone signals that the field is moving beyond preclinical models into standardized, rigorously compared human trials. One finalist, NanoTitan, plans to commercialize its technology through a spinout, illustrating how the prize structure is already accelerating the path from lab to market.
Read more →